Agreement between Micromet and Lonza for antibody for hematologic cancers

On November 24 2009 Micromet Inc entered into an agreement with Lonza AG for the process development and manufacture of blinatumomab (MT103), a BiTE antibody being investigated for the treatment of various hematologic cancers. Micromet controls the worldwide rights to develop and commercialise blinatumomab after it reacquired MedImmune’s remaining rights to this product candidate on November 4 2009. Under the terms of the agreement, Lonza will manufacture blinatumomab for clinical trials. In addition, Lonza will develop the commercial scale process and will supply blinatumomab for the market if so requested by Micromet.